Stoke Therapeutics, Inc. Defined Contribution Plan, Cost
Stoke Therapeutics, Inc. (STOK) reported Defined Contribution Plan, Cost of $1.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-16
- Stoke Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2020-12-31 was -$40.00K.
- Stoke Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2020-09-30 was $80.00K.
- Stoke Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2020-06-30 was $160.00K.
- Stoke Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2020-03-31 was $80.00K.
- Stoke Therapeutics, Inc. defined contribution plan, cost for fiscal 2025 was $1.10M, a 37.50% increase from fiscal 2024.
- Stoke Therapeutics, Inc. defined contribution plan, cost for fiscal 2024 was $800.00K, a 14.29% increase from fiscal 2023.
- Stoke Therapeutics, Inc. defined contribution plan, cost for fiscal 2023 was $700.00K, a 16.67% increase from fiscal 2022.
- Stoke Therapeutics, Inc. defined contribution plan, cost for fiscal 2022 was $600.00K, a 20.00% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.10M 10-K · filed 2026-03-16 | ||||
| 2024-12-31 | $800.00K 10-K · filed 2026-03-16 | ||||
| 2023-12-31 | $700.00K 10-K · filed 2025-03-18 | ||||
| 2022-12-31 | $600.00K 10-K · filed 2024-03-25 | ||||
| 2021-12-31 | $500.00K 10-K · filed 2023-03-06 | ||||
| 2020-12-31 | -$40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $40.00K derived: sum of 2 quarters · filed 2022-03-10 | $200.00K derived: sum of 3 quarters · filed 2022-03-10 | $200.00K 10-K · filed 2022-03-10 | $20.00K 10-K · filed 2021-03-09 |
| 2020-09-30 | $80.00K 10-Q · filed 2020-11-12 | $240.00K derived: sum of 2 quarters · filed 2020-11-12 | $240.00K 10-Q · filed 2020-11-12 | $320.00K derived: sum of 4 quarters · filed 2021-03-09 | |
| 2020-06-30 | $160.00K 10-Q · filed 2020-08-10 | $80.00K 10-Q · filed 2020-08-10 | $240.00K derived: sum of 3 quarters · filed 2021-03-09 | $240.00K derived: sum of 4 quarters · filed 2021-03-09 | |
| 2020-03-31 | $80.00K 10-Q · filed 2020-05-15 | $80.00K derived: sum of 2 quarters · filed 2021-03-09 | $80.00K derived: sum of 3 quarters · filed 2021-03-09 | $80.00K derived: sum of 4 quarters · filed 2021-03-09 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $0.00 derived: sum of 2 quarters · filed 2021-03-09 | $0.00 derived: sum of 3 quarters · filed 2021-03-09 | $0.00 10-K · filed 2021-03-09 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $0.00 derived: sum of 3 quarters · filed 2020-08-10 | $0.00 derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-05-15 | $0.00 derived: sum of 3 quarters · filed 2020-05-15 | $0.00 derived: sum of 4 quarters · filed 2020-05-15 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $0.00 derived: sum of 2 quarters · filed 2020-03-23 | $0.00 derived: sum of 3 quarters · filed 2020-03-23 | $0.00 10-K · filed 2020-03-23 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |